Shares of AVITA MED LTD/S ADR (NASDAQ:RCEL) shot up 1.6% during trading on Wednesday . The stock traded as high as $10.25 and last traded at $10.20, 21,427 shares were traded during trading. A decline of 95% from the average session volume of 408,126 shares. The stock had previously closed at $10.04.
A number of equities analysts have weighed in on the stock. ValuEngine downgraded shares of AVITA MED LTD/S from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Lake Street Capital lifted their price target on shares of AVITA MED LTD/S from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Zacks Investment Research raised shares of AVITA MED LTD/S from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Friday, November 29th.
The stock has a market cap of $846.86 million, a PE ratio of -26.62 and a beta of 1.27. The business’s fifty day simple moving average is $8.71.
An institutional investor recently bought a new position in AVITA MED LTD/S stock. Larson Financial Group LLC acquired a new position in AVITA MED LTD/S ADR (NASDAQ:RCEL) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,369 shares of the company’s stock, valued at approximately $31,000. 0.01% of the stock is currently owned by hedge funds and other institutional investors.
AVITA MED LTD/S Company Profile (NASDAQ:RCEL)
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin.